Oncolytics Biotech Inc. (NASDAQ:ONCY – Get Rating) – Investment analysts at HC Wainwright dropped their Q1 2023 earnings per share estimates for Oncolytics Biotech in a research report issued to clients and investors on Tuesday, March 14th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.07) for the quarter, down from their prior forecast of ($0.05). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q2 2023 earnings at ($0.07) EPS, Q3 2023 earnings at ($0.06) EPS, Q4 2023 earnings at ($0.06) EPS, FY2023 earnings at ($0.26) EPS, FY2024 earnings at ($0.23) EPS and FY2025 earnings at ($0.20) EPS.
ONCY has been the topic of several other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Oncolytics Biotech in a research note on Monday, March 6th. Canaccord Genuity Group dropped their target price on shares of Oncolytics Biotech from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, March 6th.
Oncolytics Biotech Stock Performance
Institutional Trading of Oncolytics Biotech
Large investors have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its stake in Oncolytics Biotech by 75.7% in the third quarter. Renaissance Technologies LLC now owns 24,600 shares of the company’s stock valued at $30,000 after buying an additional 10,600 shares during the last quarter. Newman Dignan & Sheerar Inc. raised its position in Oncolytics Biotech by 46.5% in the 4th quarter. Newman Dignan & Sheerar Inc. now owns 18,915 shares of the company’s stock valued at $31,000 after purchasing an additional 6,000 shares during the last quarter. Toronto Dominion Bank acquired a new stake in Oncolytics Biotech during the 2nd quarter worth $34,000. Lynwood Capital Management Inc. acquired a new stake in Oncolytics Biotech during the 4th quarter worth $41,000. Finally, Virtu Financial LLC purchased a new stake in shares of Oncolytics Biotech in the fourth quarter valued at about $41,000. 1.20% of the stock is owned by institutional investors and hedge funds.
Oncolytics Biotech Company Profile
Oncolytics Biotech, Inc engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses.
- Get a free copy of the StockNews.com research report on Oncolytics Biotech (ONCY)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.